UCB:EBR
UCB
204,60 €
arrow_downward
−0,68%(−1,40) 1D
16. lis, 17:37:21 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za UCB...
Otvori
204,50 €
Najviša
205,10 €
Najniža
201,30 €
Trž. kap.
39,39 mlr.
Prosj. kol.
248,57 tis.
Količina
324,45 tis.
Dividenda
0,50 %
Kvartalna dividenda
0,25 €
Datum nakon isplate dividende
4. svi 2026.
P/E omjer
18,09
52-tjed. najviša
289,50 €
52-tjed. najniža
197,45 €
EPS
11,31 €
Dionice u optjecaju
194,51 mil.
Broj djelatnika
9 tis.
Otvori
204,50 €
Najviša
205,10 €
Najniža
201,30 €
Trž. kap.
39,39 mlr.
Prosj. kol.
248,57 tis.
Količina
324,45 tis.
Dividenda
0,50 %
Kvartalna dividenda
0,25 €
Datum nakon isplate dividende
4. svi 2026.
P/E omjer
18,09
52-tjed. najviša
289,50 €
52-tjed. najniža
197,45 €
EPS
11,31 €
Dionice u optjecaju
194,51 mil.
Broj djelatnika
9 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
ad-hoc-news.de
·
prije 1 dan
UCB launches Wear It Out: what it means for UCB stock
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
UCB – informacije
Glavni izvršni direktorJean-Christophe Tellier
Zaposlenici9 tis.
Osnovano18. sij 1928.
Sjedište-
Sektor-
Web-lokacijaucb.com